Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Indian Avastin Biosimilar Arrives Amid Roche's Charges

Executive Summary

Reliance Life Sciences has introduced its biosimilar version of Roche's anticancer, Avastin (bevacizumab), on the Indian market but the Swiss multinational has claimed it is unconvinced of the rigor involved in the regulatory scrutiny of the product.

Advertisement

Related Content

Interview: German Merck Set For Big "Leap" In India
Roche Fears 'Real' Biosimilar Competition Says Russia's Biocad
Litigation Aside Biosimilar Avastin Just Got Cheaper In India
Indian Avastin Versions Head For Debut; Watch Off-Label Space
India Avastin Off-Label Use: Roche Defines Responsibility
INTERVIEW: Lupin head on US plans, fair biosimilar pricing and 'letting go'
Roche draws emerging markets battle lines with launch of cut-price Herceptin and MabThera in India

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC065391

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel